Are Stimulants Useful in ASC? / L. Eugene ARNOLD

Public ISBD in Autism Spectrum Conditions / Sven BÖLTE Titre : Are Stimulants Useful in ASC? Type de document : Texte imprimé et/ou numérique Auteurs : L. Eugene ARNOLD, Auteur ; Michael G. AMAN, Auteur ; Benjamin L. HANDEN, Auteur Année de publication : 2011 Importance : p.217-219 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=139 in Autism Spectrum Conditions / Sven BÖLTE Are Stimulants Useful in ASC? [Texte imprimé et/ou numérique] / L. Eugene ARNOLD, Auteur ; Michael G. AMAN, Auteur ; Benjamin L. HANDEN, Auteur . - 2011 . - p.217-219. Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=139

Exemplaires

Code-barres	Cote	Support	Localisation	Section	Disponibilité
aucun exemplaire

Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder / Craig A. ERICKSON in Journal of Autism and Developmental Disorders, 55-9 (September 2025)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3387-3394 Titre : Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Craig A. ERICKSON, Auteur ; Rebecca C. SHAFFER, Auteur ; Meredith WILL, Auteur ; Lauren M. SCHMITT, Auteur ; Paul HORN, Auteur ; Kathy HIRST, Auteur ; Ernest V. PEDAPATI, Auteur ; Nicole OBER, Auteur ; Rameshwari V. TUMULURU, Auteur ; Benjamin L. HANDEN, Auteur ; David Q. BEVERSDORF, Auteur Article en page(s) : p.3387-3394 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12-22 year olds (mean age 17.4 years; range 12.9-22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug. En ligne : https://doi.org/10.1007/s10803-023-06132-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566 [article] Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Craig A. ERICKSON, Auteur ; Rebecca C. SHAFFER, Auteur ; Meredith WILL, Auteur ; Lauren M. SCHMITT, Auteur ; Paul HORN, Auteur ; Kathy HIRST, Auteur ; Ernest V. PEDAPATI, Auteur ; Nicole OBER, Auteur ; Rameshwari V. TUMULURU, Auteur ; Benjamin L. HANDEN, Auteur ; David Q. BEVERSDORF, Auteur . - p.3387-3394. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3387-3394 Index. décimale : PER Périodiques Résumé : Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12-22 year olds (mean age 17.4 years; range 12.9-22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug. En ligne : https://doi.org/10.1007/s10803-023-06132-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566

Differences in verbal and nonverbal IQ test scores in children with autism spectrum disorder / Sabrina N. GRONDHUIS in Research in Autism Spectrum Disorders, 49 (May 2018)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 49 (May 2018) . - p.47-55 Titre : Differences in verbal and nonverbal IQ test scores in children with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Sabrina N. GRONDHUIS, Auteur ; Luc LECAVALIER, Auteur ; L. Eugene ARNOLD, Auteur ; Benjamin L. HANDEN, Auteur ; Lawrence SCAHILL, Auteur ; Christopher J. MCDOUGLE, Auteur ; Michael G. AMAN, Auteur Article en page(s) : p.47-55 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  ASD  Intelligence  IQ  Language  Assessment Index. décimale : PER Périodiques Résumé : Background Intelligence tests are a fundamental component of diagnostic assessments for children with suspected autism spectrum disorder (ASD). There are many assessments available, but scores across tests may not be comparable in children with ASD. Method Eighty children (68 boys) age 4–14 years with ASD completed the Stanford-Binet Intelligence Scales, 5th Edition (SB5), a verbal measure of intelligence, and the Leiter International Performance Scale – Revised (Leiter-R), a nonverbal measure of intelligence. Results Although discrepancies went in both directions, we found significantly higher mean scores on the Leiter-R than SB5 (9.6 point difference). Children younger than 8 years had more pronounced discrepancies (13.8 points vs. 3.5 points for >8?years), and children with less-developed language skills had greater discrepancies (13.1 points vs. 5.8 points for higher language skills). Conclusion This suggests these IQ tests are not interchangeable and language demands may produce different results that could impact clinician interpretation. Both clinicians and researchers should be aware of the likely impact of adopting primarily verbal vs. nonverbal tests when assessing children with ASD, especially those with less language. En ligne : https://doi.org/10.1016/j.rasd.2018.02.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=340 [article] Differences in verbal and nonverbal IQ test scores in children with autism spectrum disorder [Texte imprimé et/ou numérique] / Sabrina N. GRONDHUIS, Auteur ; Luc LECAVALIER, Auteur ; L. Eugene ARNOLD, Auteur ; Benjamin L. HANDEN, Auteur ; Lawrence SCAHILL, Auteur ; Christopher J. MCDOUGLE, Auteur ; Michael G. AMAN, Auteur . - p.47-55. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 49 (May 2018) . - p.47-55 Mots-clés : Autism spectrum disorder  ASD  Intelligence  IQ  Language  Assessment Index. décimale : PER Périodiques Résumé : Background Intelligence tests are a fundamental component of diagnostic assessments for children with suspected autism spectrum disorder (ASD). There are many assessments available, but scores across tests may not be comparable in children with ASD. Method Eighty children (68 boys) age 4–14 years with ASD completed the Stanford-Binet Intelligence Scales, 5th Edition (SB5), a verbal measure of intelligence, and the Leiter International Performance Scale – Revised (Leiter-R), a nonverbal measure of intelligence. Results Although discrepancies went in both directions, we found significantly higher mean scores on the Leiter-R than SB5 (9.6 point difference). Children younger than 8 years had more pronounced discrepancies (13.8 points vs. 3.5 points for >8?years), and children with less-developed language skills had greater discrepancies (13.1 points vs. 5.8 points for higher language skills). Conclusion This suggests these IQ tests are not interchangeable and language demands may produce different results that could impact clinician interpretation. Both clinicians and researchers should be aware of the likely impact of adopting primarily verbal vs. nonverbal tests when assessing children with ASD, especially those with less language. En ligne : https://doi.org/10.1016/j.rasd.2018.02.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=340

A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder / Benjamin L. HANDEN in Journal of Autism and Developmental Disorders, 39-5 (May 2009)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 39-5 (May 2009) . - p.796-805 Titre : A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Benjamin L. HANDEN, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; Raun D. MELMED, Auteur ; David L. BURNHAM, Auteur ; Jon B. BRUSS, Auteur ; David J. HANSEN, Auteur Année de publication : 2009 Article en page(s) : p.796-805 Langues : Anglais (eng) Mots-clés : Autism Gastrointestinal-symptoms Oral-human immunoglobulin Index. décimale : PER Périodiques Résumé : Controversy exists regarding the extent and possible causal relationship between gastrointestinal symptoms and autism. A randomized, double-blind, placebo-controlled, parallel groups, dose-ranging study of oral, human immunoglobulin (IGOH 140, 420, or 840 mg/day) was utilized with 125 children (ages 2–17 years) with autism and persistent GI symptoms. Endpoint analysis revealed no significant differences across treatment groups on a modified global improvement scale (validated in irritable bowel syndrome studies), number of daily bowel movements, days of constipation, or severity of problem behaviors. IGOH was well-tolerated; there were no serious adverse events. This study demonstrates the importance of conducting rigorous trials in children with autism and casts doubt on one GI mechanism presumed to exert etiological and/or symptomatic effects in this population. En ligne : http://dx.doi.org/10.1007/s10803-008-0687-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=733 [article] A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder [Texte imprimé et/ou numérique] / Benjamin L. HANDEN, Auteur ; Michael G. AMAN, Auteur ; Christopher J. MCDOUGLE, Auteur ; Raun D. MELMED, Auteur ; David L. BURNHAM, Auteur ; Jon B. BRUSS, Auteur ; David J. HANSEN, Auteur . - 2009 . - p.796-805. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 39-5 (May 2009) . - p.796-805 Mots-clés : Autism Gastrointestinal-symptoms Oral-human immunoglobulin Index. décimale : PER Périodiques Résumé : Controversy exists regarding the extent and possible causal relationship between gastrointestinal symptoms and autism. A randomized, double-blind, placebo-controlled, parallel groups, dose-ranging study of oral, human immunoglobulin (IGOH 140, 420, or 840 mg/day) was utilized with 125 children (ages 2–17 years) with autism and persistent GI symptoms. Endpoint analysis revealed no significant differences across treatment groups on a modified global improvement scale (validated in irritable bowel syndrome studies), number of daily bowel movements, days of constipation, or severity of problem behaviors. IGOH was well-tolerated; there were no serious adverse events. This study demonstrates the importance of conducting rigorous trials in children with autism and casts doubt on one GI mechanism presumed to exert etiological and/or symptomatic effects in this population. En ligne : http://dx.doi.org/10.1007/s10803-008-0687-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=733

Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder / Luc LECAVALIER in Journal of Autism and Developmental Disorders, 44-5 (May 2014)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 44-5 (May 2014) . - p.1128-1143 Titre : Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Luc LECAVALIER, Auteur ; Jeffrey J. WOOD, Auteur ; Alycia K. HALLADAY, Auteur ; Nancy E. JONES, Auteur ; Michael G. AMAN, Auteur ; Edwin H. Jr COOK, Auteur ; Benjamin L. HANDEN, Auteur ; Bryan H. KING, Auteur ; Deborah A. PEARSON, Auteur ; Victoria HALLETT, Auteur ; Katherine Anne SULLIVAN, Auteur ; Sabrina N. GRONDHUIS, Auteur ; Somer L. BISHOP, Auteur ; Joseph P. HORRIGAN, Auteur ; Geraldine DAWSON, Auteur ; Lawrence SCAHILL, Auteur Année de publication : 2014 Article en page(s) : p.1128-1143 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Anxiety  Instrument  Measure  Assessment  Treatment  Intervention Index. décimale : PER Périodiques Résumé : Despite the high rate of anxiety in individuals with autism spectrum disorder (ASD), measuring anxiety in ASD is fraught with uncertainty. This is due, in part, to incomplete consensus on the manifestations of anxiety in this population. Autism Speaks assembled a panel of experts to conduct a systematic review of available measures for anxiety in youth with ASD. To complete the review, the panel held monthly conference calls and two face-to-face meetings over a fourteen-month period. Thirty eight published studies were reviewed and ten assessment measures were examined: four were deemed appropriate for use in clinical trials, although with conditions; three were judged to be potentially appropriate, while three were considered not useful for clinical trials assessing anxiety. Despite recent advances, additional relevant, reliable and valid outcome measures are needed to evaluate treatments for anxiety in ASD. En ligne : http://dx.doi.org/10.1007/s10803-013-1974-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=232 [article] Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Luc LECAVALIER, Auteur ; Jeffrey J. WOOD, Auteur ; Alycia K. HALLADAY, Auteur ; Nancy E. JONES, Auteur ; Michael G. AMAN, Auteur ; Edwin H. Jr COOK, Auteur ; Benjamin L. HANDEN, Auteur ; Bryan H. KING, Auteur ; Deborah A. PEARSON, Auteur ; Victoria HALLETT, Auteur ; Katherine Anne SULLIVAN, Auteur ; Sabrina N. GRONDHUIS, Auteur ; Somer L. BISHOP, Auteur ; Joseph P. HORRIGAN, Auteur ; Geraldine DAWSON, Auteur ; Lawrence SCAHILL, Auteur . - 2014 . - p.1128-1143. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 44-5 (May 2014) . - p.1128-1143 Mots-clés : Autism spectrum disorder  Anxiety  Instrument  Measure  Assessment  Treatment  Intervention Index. décimale : PER Périodiques Résumé : Despite the high rate of anxiety in individuals with autism spectrum disorder (ASD), measuring anxiety in ASD is fraught with uncertainty. This is due, in part, to incomplete consensus on the manifestations of anxiety in this population. Autism Speaks assembled a panel of experts to conduct a systematic review of available measures for anxiety in youth with ASD. To complete the review, the panel held monthly conference calls and two face-to-face meetings over a fourteen-month period. Thirty eight published studies were reviewed and ten assessment measures were examined: four were deemed appropriate for use in clinical trials, although with conditions; three were judged to be potentially appropriate, while three were considered not useful for clinical trials assessing anxiety. Despite recent advances, additional relevant, reliable and valid outcome measures are needed to evaluate treatments for anxiety in ASD. En ligne : http://dx.doi.org/10.1007/s10803-013-1974-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=232

Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder / Lawrence SCAHILL in Autism, 19-1 (January 2015)  

Permalink

A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges / Laura SILVERMAN in Research in Autism Spectrum Disorders, 8-7 (July 2014)  

Permalink

Parent Training for Disruptive Behavior. The RUBI Autism Network, Clinician Manual / Karen E. BEARSS

Permalink

Parent Training for Disruptive Behavior. The RUBI Autism Network, Parent Workbook / Karen E. BEARSS

Permalink

A Pilot Study of Parent Training in Young Children with Autism Spectrum Disorders and Disruptive Behavior / Karen E. BEARSS in Journal of Autism and Developmental Disorders, 43-4 (April 2013)  

Permalink

Practitioner Review: Psychopharmacology in children and adolescents with mental retardation / Benjamin L. HANDEN in Journal of Child Psychology and Psychiatry, 47-9 (September 2006)  

Permalink

Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems / Cristan A. FARMER in Journal of Autism and Developmental Disorders, 42-6 (June 2012)  

Permalink

Le programme RUBI pour gérer les comportements perturbateurs / Karen BEARSS

Permalink

A Prospective Study of the Concordance of DSM-IV and DSM-5 Diagnostic Criteria for Autism Spectrum Disorder / Micah O. MAZUREK in Journal of Autism and Developmental Disorders, 47-9 (September 2017)  

Permalink

The Autism Impact Measure (AIM): Initial Development of a New Tool for Treatment Outcome Measurement / Stephen M. KANNE in Journal of Autism and Developmental Disorders, 44-1 (January 2014)  

Permalink

---

1 2 (1 - 15 / 18) Par page : Tout afficher